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microRNA expression profiling on 
individual breast cancer patients 
identifies novel panel of circulating 
microRNA for early detection
Rimi Hamam1, Arwa M. Ali2,3, Khalid A. Alsaleh2, Moustapha Kassem1,4, Musaed Alfayez1, 
Abdullah Aldahmash1,5 & Nehad M. Alajez1
Breast cancer (BC) is the most common cancer type and the second cause of cancer-related death 
among women. Therefore, better understanding of breast cancer tumor biology and the identification 
of novel biomarkers is essential for the early diagnosis and for better disease stratification and 
management choices. Herein we developed a novel approach which relies on the isolation of circulating 
microRNAs through an enrichment step using speed-vacuum concentration which resulted in 
5-fold increase in microRNA abundance. Global miRNA microarray expression profiling performed 
on individual samples from 23 BC and 9 normals identified 18 up-regulated miRNAs in BC patients 
(p(corr) < 0.05). Nine miRNAs (hsa-miR-4270, hsa-miR-1225-5p, hsa-miR-188-5p, hsa-miR-1202,  
hsa-miR-4281, hsa-miR-1207-5p, hsa-miR-642b-3p, hsa-miR-1290, and hsa-miR-3141) were 
subsequently validated using qRT-PCR in a cohort of 46 BC and 14 controls. The expression of those 
microRNAs was overall higher in patients with stage I, II, and III, compared to stage IV, with potential 
utilization for early detection. The expression of this microRNA panel was slightly higher in the HER2 
and TN compared to patients with luminal subtype. Therefore, we developed a novel approach which 
led to the identification of a novel microRNA panel which was upregulated in BC patients with potential 
utilization in disease diagnosis and stratification.
Despite recent advances in cancer management and therapy, cancer remains the second leading cause of death 
worldwide. Breast cancer (BC) is the most common cancer type and the second cause of cancer-related mortality 
among women. Annually, the number of women who are newly diagnosed with breast cancer is going to exceed 
235,000 and there are around 40,000 deaths as a result of breast cancer in the United States1. In the Kingdom 
of Saudi Arabia, breast cancer is the ninth leading cause of death among women in 20102. Furthermore, breast 
cancer constitutes around 25% of all new registered cancer incidence among Saudi women whereas 1,308 new 
breast cancer cases were reported during the year 20092. The incidence rate of breast cancer in Saudi Arabia is also 
expected to increase over the next decades as a result of the population’s growth and aging.
Better understanding of breast cancer tumor biology and the identification of novel biomarkers is essential 
for the early diagnosis and for better disease stratification and management choices. During the recent years, 
microRNA (miRNA) has become increasingly recognized as important regulator of both normal and cancer cell 
biology3–5. Global profiling of cancer tissue versus normal tissue has identified several dysregulated miRNAs in 
different human cancers6–8. However, this approach requires invasive procedures such as biopsy or surgical inter-
vention in order to acquire the representative tissue to be analyzed. Therefore, finding a non-invasive approach 
for early diagnosis and management of different human disease, such as cancer, has always been challenging task. 
Several studies have reported the potential utilization of circulating biomarkers in different body fluids, such 
as serum and plasma, as diagnostic and prognostic tools for different types of cancers, while some studies have 
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reported the use of circulating miRNA for cancer detection and prognostic stratification. However, one limita-
tion of the previous studies is that these studies most often examined the expression of defined set of miRNAs or 
pooled samples from different patients and then assessed miRNA expression using qRT-PCR or other methods, 
which limits the novelty of the identified miRNA as well as the inability to perform individual data analysis as 
related to disease condition9–12. In current study, we established a novel and unbiased approach where we isolated 
circulating miRNAs from breast cancer patients, we employed speed-vacuum centrifugation step to increase the 
abundance of miRNAs and subsequently conducted global miRNA profiling on individual patient specimens. 
Our approach led to the identification of a novel 18-microRNA panel which was upregulated in breast cancer 
patients as early as Stage I and Stage II.
Results
Distinct microRNA expression profile in patients with breast cancer compared to healthy controls. 
Circulating RNAs were isolated using Norgen’s slurry format kit. To further increase the concentration of iso-
lated RNA, we utilized speed-vacuum concentration approach. As shown in supplementary Fig. 1, this approach 
increased the detection limit for circulating miRNA in these samples ~4.6 fold. Circulating miRNAs were identi-
fied by performing global miRNA microarray expression profiling on 23 breast cancer and 9 normal control sam-
ples. Using Benjamini-Hochberg False Discovery Rate (FDR) multiple testing correction method (p(corr) < 0.05) 
and two-fold change cut-off, we identified 18 up-regulated miRNAs in samples obtained from patients with 
breast cancer compared to healthy controls. Individual data are presented in the heatmap in Fig. 1. Breast can-
cer-associated miRNAs identified were: hsa-miR-4270, hsa-miR-1225-5p, hsa-miR-188-5p, hsa-miR-1202, hsa-
miR-4281, hsa-miR-1207-5p, hsa-miR-642b-3p, hsa-miR-1290, hsa-miR-3141, hsa-miR-150-3p, hsa-miR-4298, 
hsa-miR-483-5p, hsa-miR-134, hsa-miR-762, hsa-miR-1914-3p, hsa-miR-34a-5p, hsa-miR-3652, and hsa-miR-
424-5p (Table 1). Among the identified miRNAs, hsa-miR-4270 was the most significantly upregulated miRNA 
in patients’ samples compared to controls (p value = 3.5 × 10−6, p value (Corr) = 0.001). The top nine miRNAs 
(based on p value, Table 1) : hsa-miR-4270, hsa-miR-1225-5p, hsa-miR-188-5p, hsa-miR-1202, hsa-miR-4281, 
Figure 1. Heatmap depicting the expression of 18 circulating miRNAs in patients with breast cancer (BC) 
compared to normal healthy controls. Heatmap of individual plasma samples of 9 control and 23 patients 
with BC. The miRNA expression levels exhibited ≥ 2.0 fold changes and p ≤ 0.05 are presented. Each column 
represents an individual sample and each row represents a single miRNA. Expression level of each miRNA in a 
single sample is depicted according to the color scale.
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hsa-miR-1207-5p, hsa-miR-642b-3p, hsa-miR-1290, and hsa-miR-3141 were subsequently chosen for further 
validation in a cohort of 46 BC and 14 normal controls, including 23 BC and 8 normals which were used for the 
Updated_systematic_name mirbase accession No p (Corr) p Regulation FC
hsa-miR-4270 MIMAT0016900 0.001193408 5.35E-06 up 182.9
hsa-miR-1225-5p MIMAT0005572 0.004337585 7.78E-05 up 22.7
hsa-miR-188-5p MIMAT0000457 0.004337585 6.59E-05 up 73.0
hsa-miR-1202 MIMAT0005865 0.006776397 1.52E-04 up 27.3
hsa-miR-4281 MIMAT0016907 0.019025994 5.12E-04 up 11.6
hsa-miR-1207-5p MIMAT0005871 0.0202241 7.26E-04 up 14.7
hsa-miR-642b-3p MIMAT0018444 0.0202241 6.99E-04 up 62.9
hsa-miR-1290 MIMAT0005880 0.022832992 9.22E-04 up 45.9
hsa-miR-3141 MIMAT0015010 0.029752607 0.001334 up 50.7
hsa-miR-150-3p MIMAT0004610 0.033017445 0.001629 up 43.7
hsa-miR-4298 MIMAT0016852 0.03568337 0.00192 up 40.2
hsa-miR-483-5p MIMAT0004761 0.038129777 0.002223 up 42.3
hsa-miR-134 MIMAT0000447 0.04201405 0.002826 up 42.2
hsa-miR-762 MIMAT0010313 0.04201405 0.0028 up 43.1
hsa-miR-1914-3p MIMAT0007890 0.044369638 0.003895 up 30.8
hsa-miR-34a-5p MIMAT0000255 0.044369638 0.004159 up 29.5
hsa-miR-3652 MIMAT0018072 0.044369638 0.003801 up 44.3
hsa-miR-424-5p MIMAT0001341 0.044369638 0.003333 up 43.0
Table 1. Differentially expressed circulating plasma miRNAs in 23 breast cancer patients compared to 9 
normal controls.
Figure 2. Validation of the expression of 9 miRNAs identified from microarray data employing plasma or 
serum from patients with breast cancer (BC, n = 46) and healthy controls (n = 14) using quantitative Real-
Time PCR. P values were calculated using unpaired t-test and are indicated on each plot. Data are presented as 
“− delta CT” using box and whiskers plots.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:25997 | DOI: 10.1038/srep25997
microarray profiling. Data presented in Fig. 2 collectively validated the microarray data. Interestingly, the expres-
sion of the nine miRNAs was slightly higher in Stage I, Stage II, and Stage III compared to Stage IV (Fig. 3). Anova 
analysis revealed significant difference in the expression of hsa-miR-4270, hsa-miR-1225-5p, hsa-miR-1202, hsa-
miR-1207, and hsa-miR-1290 as function of cancer stage. When the expression of those nine miRNAs was plotted 
as function of breast cancer molecular subtype, similar trends of miRNA expression were overall seen, whereas 
the expression was slightly higher in the HER2 and TN compared to the luminal cancer subtype. Additionally, 
patients with the luminal subtype exhibited the largest degree of heterogeneity, possibly due to further luminal 
A/B sub classification (Fig. 4).
Discussion
Identifying reliable blood biomarkers for early diagnosis or prognostic stratification of various human diseases 
is an area of intensive investigation. Proteins, DNA, and mRNA could be detected in the circulation of cancer 
patients and have been suggested in some studies to reflect disease activity13–15. miRNAs have recently emerged as 
providing reliable biomarkers for disease status in a number of cancer patients as well as in other diseases, due to 
their stability and ease of detection10,16,17. Current protocols employed to detect circulating miRNAs rely mostly 
on using either a PCR-based method for measuring the expression of selected panel of miRNAs or the utilization 
of pooled serum/plasma samples and running a more robust assay such as miRNA microarrays. However, these 
approaches in general do not lead to the identification of novel miRNA or studying their relevance at the indi-
vidual patient’s level. In our studies we have employed individual patients’ and control’s samples and utilized an 
unbiased discovery approach using miRNA microarray profiling.
Several of the established protocols for miRNA isolation from serum and plasma require a large sample vol-
ume to obtain sufficient RNA for down-stream analysis. Thus, clinical serum and plasma samples from several 
patients are frequently pooled10,18, which may compromise statistical analyses by preventing using the individual 
patient as the statistical unit, that may lead to erroneous conclusions. In our study, we have avoided this limitation 
as we developed a novel approach which relies on the isolation of circulating microRNAs through an enrich-
ment step using speed-vacuum concentration that resulted in ~5-fold enrichment. In addition, we employed an 
unbiased discovery approach through using microarray chips which can detect more than 1700 human-specific 
miRNAs.
Figure 3. Expression of 9 circulating miRNAs according to breast cancer stage. The expression of a group of 
9 circulating miRNAs measured using qRT-PCR in normal (n = 14) or patients with breast cancer (BC, n = 46) 
are plotted as a function of cancer stage. P values were calculated using unpaired t-test. Data are presented 
as “− delta CT” using box and whiskers plots. *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005, n.s., not 
significant.
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We identified 18 novel miRNAs, which were upregulated in BC patients compared to matched healthy con-
trols. The expression of nine selected miRNAs was subsequently validated in a cohort of 46 breast cancer and 14 
normal subjects, which collectively corroborated the microarray data.
Some of the identified miRNAs have previously been reported to be associated with a number of human dis-
eases, hsa-miR-134 is upregulated sera of patients with acute myocardial infarction19 while hsa-miR-483-5p levels 
were increased in sera of patients with adrenocortical tumors and pulmonary tuberculosis20,21. Elevated expres-
sion of hsa-miR-1290 was reported in prostate cancer and in fatty liver disease22,23. To our knowledge, none of 
the other miRNAs identified in our study has been reported to be enriched in the circulation of other human dis-
eases. Interestingly, those miRNAs were also detected in the circulation of BC patients with early stage (I and II), 
which suggest potential utilization of this miRNA panel for early detection.
Some miRNAs which have been reported to be enriched in breast cancer tissues, such as hsa-miR-21 and 
hsa-miR-155, were not significantly upregulated in the circulation of breast cancer patients in our study. Therefore 
our data suggest that circulating microRNAs are unlikely to be derived from the tumor itself, but rather reflect 
the generalized homeostatic responses during health and disease. In support of this hypothesis, pathway analysis 
on the predicted gene targets for the identified miRNAs revealed potential role in important cellular processes 
(supplementary Fig. 2). Also, hsa-miR-1202 has recently been reported to be down-regulated in patients with 
depression24 and thus mental state may contribute to some changes in circulating miRNAs profile. In addition, 
we observed upregulated expression of two HSV2 miRNAs in the circulation of breast cancer patients (supple-
mentary Fig. 3).
In conclusion, we have identified a novel panel consisting of 18 circulating miRNAs that is enriched in patients 
with breast cancer and their presence was higher in patients with stage I, II , and III suggesting it possible uti-
lization for early diagnosis and disease stratification. Similar strategy and methodology can also be utilized for 
detecting circulating miRNAs in other human diseases.
Materials and Methods
Ethics statement. The clinical study and blood collection were approved by Institutional Research Ethics 
Board at the King Saud University College of Medicine (Riyadh, Riyadh, Saudi Arabia). The methods were carried 
out in accordance with the approved guidelines. Informed consent was obtained from all subjects.
Figure 4. Expression of 9 circulating miRNAs according to breast cancer molecular subtype. The expression 
of a group of 9 circulating miRNAs measured using qRT-PCR in normal (n = 14) or patients with breast 
cancer (BC, n = 46) are plotted as a function of BC molecular type. P values were calculated using unpaired 
t-test. Data are presented as “− delta CT” using box and whiskers plots. *p < 0.05, **p < 0.005, ***p < 0.0005, 
****p < 0.00005, n.s., not significant, TN: triple negative, HER2: HER2+ .
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Patient and blood collection. Blood samples from 46 breast cancer patients were obtained from patients 
undergoing standard treatment at the King Khaled University Hospital (Riyadh, Saudi Arabia). Controls samples 
were obtained from 14 healthy women. The clinical information of subjects included in current study and their 
tumor characteristics are listed in Table 2. Samples with signs of hemolysis were excluded from the study.
Plasma and serum preparation and total RNA isolation. Plasma and serum were prepared from 
freshly collected whole blood samples (EDTA-coated tubes for plasma collection or regular tubes for serum col-
lection) by centrifugation at 2,000 rpm for 15 minutes at room temperature. Collected plasma and serum were 
frozen at − 80 °C. Circulating RNAs were extracted from ~3.5 mL of the collected plasma or serum using Norgen’s 
Plasma/Serum Circulating and Exosomal RNA Purification Kit Slurry Format (Norgen Biotek, Thorold, Ontario, 
Canada) according to the manufacturer’s protocol, followed by RNA elution in 100 μl of elution buffer. Twenty 
five μl of the purified total RNA were dried by speed-vacuum centrifugation (60 minutes at RT), and were then 
reconstituted in five μl of DNAse and RNAse-free water (5-fold enrichment). Normalization across samples was 
done by using equal volume of input plasma or serum (~3.5 ml) for miRNA isolation from each sample. Isolated 
miRNA fraction was subsequently used for global miRNA profiling by microarray (after drying and reconstitu-
tion) or by qRT-PCR (without drying and reconstitution).
miRNA expression profiling. miRNA expression profiling was conducted on the isolated miRNA fraction 
from 23 patients with breast cancer and nine normals. Two microliter of the extracted RNA (after 5-fold con-
centration) was labeled and subsequently hybridized to the Agilent Human SurePrint G3 8 × 60 k v21 miRNA 
microarray chip as described before6. Subsequently, data were imported into GeneSpring 13.0 software for anal-
ysis (Agilent Technologies). Differentially expressed miRNAs in cancer patients versus healthy control samples 
were determined using a corrected p-value (≤ 0.05, Benjamini-Hochberg multiple testing correction method). 
MicroRNAs showing ≥ 2.0 fold change were considered significant.
miRNA validation by qRT-PCR. Validation of selected number of miRNA was carried out on circulating 
miRNA fraction isolated from either plasma or serum samples from 46 BC and 14 controls. Validation was con-
ducted using the miProfile™ Custom miRNA qPCR Array (GeneCopoeia, Rockville, MD, United States). For 
miRNA expression detection, five μ l of the purified total RNA were used as input according to the manufacturer’s 
protocol. All primers used in the current study were provided by GeneCopoeia, except for hsa-miR-21 primers 
which were obtained from Applied Biosystems. The relative expression levels were expressed as “− delta CT” of 
breast cancer patients compared to normal controls. Quantification of hsa-miR-21 in plasma samples before and 
after speed vacuum concentration was conducted using Taqman microRNA assay kit (Applied Biosystems, USA) 
as described before5.
Cancer N = 46 %
Age, y
 Median age 50 y
 Range 27–71 y
Gender
 Female 46 100%
Stage
 I 3 6.5%
 II 17 37.0%
 III 10 21.7%
 IV 13 28.3%
 NA 3 6.5%
Molecular Subtype
 Luminal 22 48%
 HER2 17 37%
 TN 7 15%
Recurrence
 Recurrent 4 8.6%
 Non Recurrent 42 91.4%
Normal N = 14
Age, y
 Median age 36.5 y
 Range 26–60 y
Table 2. clinical information of patients included in current study and their tumor characteristics and 
normal control. HER2: HER2+ , TN: Triple Negative.
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Molecular profiling of breast cancer patients. Molecular profiling of BC patients was conducted in accordance 
with previously published criteria and based on the pathological characteristics of patients utilized in current 
study25,26.
Statistical analysis. Statistical analyses and graphing were conducted using GraphPad Prism 6.0 software 
(GraphPad, San Diego, CA, USA). P-values were calculated using the two-tailed t-test or one way anova analysis.
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